Theravance biopharma, inc. (TBPH)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net loss

-236,455

-215,524

-285,405

-190,669

-182,219

-237,038

-156,284

-9,575

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

6,441

4,481

3,801

3,119

2,989

3,274

2,653

3,251

Amortization and accretion income, net

3,451

1,315

-226

-

-

-

-

-

Amortization of premium on marketable securities

-

-

-

-

-

-

-

0

Share-based compensation

60,450

51,313

49,145

41,169

54,050

43,234

22,476

21,323

Net gain from the sale of VIBATIV business

-

6,056

-

-

-

-

-

-

Other-than-temporary impairment loss

-

-

8,000

-

0

-

-

-

Inventory write-down

-

-

740

303

2,096

2,887

0

0

Amortization of right-of-use assets

3,224

-

-

-

-

-

-

-

Excess tax benefits from share-based compensation

-

-

-

21

-75

282

0

0

Amounts due from TRC, LLC

23,152

5,152

-

-

-

-

-

-

Non-cash revenue from collaboration arrangements

-

-

-

-

8,000

0

0

-

Other

-146

43

-10

-182

65

0

-20

-196

Changes in operating assets and liabilities:
Accounts receivable

-620

-1,633

1,607

-1,276

1,633

90

199

0

Receivables from collaborative and licensing arrangements

11,943

2,944

-1,967

-26,156

33,392

906

-7

617

Receivable from Innoviva, Inc

-

-

-

-

-

-14,635

0

0

Prepaid taxes

-

-

-2,788

-9,522

12,764

0

0

-

Other prepaid and current assets

634

2,400

1,489

-2,710

-963

2,878

-19

388

Inventories

-

1,629

7,301

3,182

-1,030

6,628

3,101

4,822

Tax receivable

3,700

-8,191

7,890

-

0

-

-

-

Other assets

358

-45

354

-184

572

211

0

0

Accounts payable

-4,274

3,575

3,796

-16,436

8,717

3,917

2,113

-1,532

Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities

10,626

-12,357

8,332

17,192

-1,039

11,680

4,170

-1,702

Accrued interest payable

2,573

1,841

21

-

-

-

-

-

Deferred rent

-

-4,308

298

632

552

-376

300

747

Deferred revenue

-31,245

69,224

17

448

295

-7,991

7,467

-124,494

Operating lease liabilities

-2,317

-

-

-

-

-

-

-

Income taxes payable

-

-

-

-

-

0

-

-

Other long-term liabilities

-4,748

-10,058

24,449

9,690

1,164

866

0

0

Net cash used in operating activities

-238,197

-112,867

-201,052

-98,989

-168,857

-175,155

-120,959

-119,107

Investing activities
Changes in restricted cash

-

-

-

-

-

833

0

-60

Purchases of property and equipment

3,176

7,240

2,406

2,135

2,647

3,107

2,734

2,590

Purchases of marketable securities

423,898

183,261

288,791

237,567

73,011

168,893

0

0

Maturities of marketable securities

339,018

347,192

234,864

91,467

186,697

65,564

0

0

Proceeds from the sale of marketable securities

5,000

20,000

-

-

-

-

-

-

Proceeds from the sale of fixed assets

5

17

-

-

-

-

-

-

Payments received on notes receivable, net of issuance

-

-

-

-

-

140

100

100

Sale of short-term investments and marketable securities

-

-

-

-

-

-878

0

0

Net cash provided by (used in) investing activities

-83,051

176,708

-56,333

-148,235

111,039

-106,251

-2,634

-2,430

Financing activities
Proceeds from the sale of ordinary shares, net

-

-

-

253,028

79,017

0

-

-

Proceeds from issuance of notes, net

-

229,441

-

222,498

-

-

-

-

Principal payment on 2033 notes

2,152

-

-

-

-

-

-

-

Proceeds from issuance of 3.250% convertible senior notes, net

-

-

-

-

0

0

-

-

Net proceeds from sale of ordinary shares under private placements

-

-

-

-

-

-

0

-

Proceeds from ESPP purchases

3,474

4,173

3,980

3,172

3,124

0

0

-

Proceeds from option exercises

3,142

1,393

6,236

4,378

0

0

-

-

Excess tax benefits from share-based compensation

-

-

-

21

-75

282

0

0

Transfers from Innoviva, Inc.

-

-

-

-

-

92,976

123,593

121,606

Repurchase of shares to satisfy tax withholding

3,173

9,807

8,560

3,871

756

178

0

0

Net cash provided by (used in) financing activities

1,291

225,200

1,656

479,226

81,310

370,621

123,593

121,537

Net increase (decrease) in cash, cash equivalents, and restricted cash

-319,957

289,041

-255,729

232,002

23,492

89,215

0

0

Cash and cash equivalents contributed from Innoviva, Inc. (Note 1)

-

-

-

-

-

277,541

0

0

Payments on notes payable and capital leases

-

-

-

-

-

-

-

69

Supplemental disclosure of cash flow information
Cash paid for interest

26,178

7,475

7,454

-

0

0

-

-

Cash paid (received) for income taxes, net

22

-7,316

4,929

-9,488

13,389

4,550

0

0

Right-of-use assets obtained in exchange for lease obligations (1)

49,847

-

-

-

-

-

-

-

Contribution of net assets, excluding cash and cash equivalents, from Innoviva, Inc. (Note 11)

-

-

-

-

-

125,337

0

0